Now available: PAX Pet Parent Report

Atopic dermatitis and other allergic conditions remain among the most challenging chronic diseases in veterinary practice. They affect not only the animal, but also the pet owner and the veterinary team managing long-term care. Persistent pruritus, recurrent flare-ups and the need for ongoing medication often lead to frustration on all sides.

Once a diagnosis has been established and relevant allergens have been identified, an essential clinical decision follows: do we continue focusing on symptomatic control, or do we take a step towards addressing the underlying cause?

Immunotherapy as a Strategic Treatment Choice

Allergen-specific immunotherapy represents a fundamentally different approach to managing allergic disease. Rather than suppressing clinical signs, immunotherapy aims to modify the immune response itself by inducing tolerance to the identified allergens. It is currently the only treatment option that targets the pathophysiology of the disease instead of providing temporary relief.

For many atopic patients, immunotherapy marks a turning point in their treatment journey. It allows the veterinary team to shift from reactive management of flare-ups to a proactive, long-term strategy focused on disease modification and improved quality of life.

Supporting Clinical Conversations with the PAX Pet Parent Report

Communicating the rationale behind immunotherapy can be challenging, particularly when owners are accustomed to fast-acting symptomatic treatments. The PAX Pet Parent Report plays a key role in bridging this gap.

More than a laboratory result, the report translates test outcomes into a clear, patient-specific narrative. It helps explain why this individual animal is experiencing symptoms and why immunotherapy is not an optional add-on, but a logical and well-founded next step in the management plan.

By providing a visual and personalised overview, the report supports veterinarians and veterinary assistants in delivering consistent, confident and comprehensible explanations during consultations.

Building Owner Confidence in Long-Term Management

When pet owners understand that immunotherapy is designed not only to reduce itching but to improve their animal’s quality of life over time, their confidence in a long-term treatment plan increases significantly. This understanding often determines whether owners remain hesitant or commit to a structured, forward-looking approach.

Clear communication transforms immunotherapy from an abstract concept into a meaningful investment in their pet’s future health.

Treating with Vision

Immunotherapy represents treatment with vision: addressing the cause of allergic disease, aiming for sustained symptom reduction and potentially decreasing reliance on other medications. The PAX Pet Parent Report supports veterinary teams in communicating this vision clearly, personally and convincingly.

The report is available via the action button next to the results in Nextview and can be shared directly with the pet owner.